Affordability and Other Barriers Despite their popularity, access to GLP-1 medications remains uneven
However, the use of these medications is controversial because they are not approved by the U.S
Sales: Up 0.7% YoY to $47.6M, missing estimates due to timing effects around the LoveBiome acquisition and a pause in consultant activity
[62] In 1998, a team of researchers at Novo Nordisk led by Lotte Bjerre Knudsen developed liraglutide, a GLP-1 receptor agonist that could be used to treat diabetes
Identification of a CXCR4 Antagonist, a T140 Analog, as an Anti-Rheumatoid Arthritis Agent
Pycnogenol has been shown to increase glutathione levels, decrease oxidative stress, and improve attention, coordination, and concentration compared to placebo